Evidence map›Paper›PMID 40670591›Full record

ArticleScientific reports2025

Exploring a circulating circRNA and miRNA biomarker panel for early detection of ovarian cancer through multiple omics analysis.

Lingxi Tian, Feng Xu, Yang Lu, Zaian Deng, Yan Gao, Jun Yang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingxi TianMOE Key Laboratory of Intelligent Biomanufacturing, School of Bioengineering, Dalian University of Technology, Dalian, 116024, China.
Feng XuDepartment of thoracic surgery, Dalian Municipal Central Hospital, Central Hospital of Dalian University of Technology, Dalian, 116033, China.
Yang LuMOE Key Laboratory of Intelligent Biomanufacturing, School of Bioengineering, Dalian University of Technology, Dalian, 116024, China.
Zaian DengCollege of health science and environmental engineering, ShenZhen Technology University, ShenZhen, 518118, China. dengzaian@sztu.edu.cn.
Yan GaoDepartment of gynecology, Liaoning Cancer hospital & Institute, Shenyang, 110044, China.
Jun YangMOE Key Laboratory of Intelligent Biomanufacturing, School of Bioengineering, Dalian University of Technology, Dalian, 116024, China. junyang@dlut.edu.cn.

Funding

Dalian Science and Technology Innovation Fund 2022JJ12SN049Fundamental Research Funds for the Central Universities DUT22YG121Fundamental Research Funds for the Central Universities DUT22YG243Fundamental Research Funds for the Central Universities DUT24YG148
6 · The paper itself

Abstract

The biological functions of circular RNA (circRNAs) in cancers have garnered significant attention, particularly for their potential as biomarkers. However, the roles of circRNAs in ovarian cancer (OC) and their applicability for early detection of this malignancy remain underexplored. We performed RNA sequencing on ovarian cancer cell lines to identify circRNAs associated with OC. The functional mechanisms of the identified circRNAs were elucidated through bioinformatics analysis. The discriminating ability of biomarkers was assessed using receiver operating characteristic (ROC) analysis. RNA sequencing analysis revealed that 170 known circRNAs were correlated with ovarian cancer. Through the circRNA-miRNA-mRNA regulatory network, we identified 9 circRNAs that interact with 8 miRNAs, subsequently regulating the expression of 324 mRNAs. Functional enrichment analysis, protein-protein interaction (PPI) network analysis, and hub gene analysis indicated that these circRNAs and miRNAs may play a role in regulating MAPK, Wnt, and ErbB signaling pathways. We validated these circRNAs and miRNAs expression profiles in cell, tissue, and plasma samples, identifying four candidates-hsa_circ_0049101, hsa_circ_0007440, hsa_circ_0006935, and hsa-miR-338-3p-that expression level positively correlate with ovarian cancer development. These markers were then combined into a circRNA and miRNA detection (CMD) panel for ovarian cancer detection. The area under the curve (AUC) values obtained from ROC analysis demonstrated that these individual candidates, as well as the CMD panel, exhibited superior discriminatory ability for OC compared to traditional biomarkers such as CA125, HE4, and the ROMA index in our sample set, which included 28 healthy controls and 22 ovarian cancer patients. Notably, the CMD panel showed exceptional potential for distinguishing early-stage OC samples from healthy controls, achieving an AUC of 1. In this study, we elucidated the functional mechanisms of a set of circRNAs associated with OC through multi-omics analysis and demonstrated that the combination of circRNAs and miRNAs into a biomarker panel holds significant potential for early detection of ovarian cancer.

Indexed as

Biomarkers, TumorEarly Detection of CancerMicroRNAsOvarian NeoplasmsRNA, CircularCell Line, TumorComputational BiologyFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMiddle AgedProtein Interaction MapsROC CurveBiomarkers, TumorMicroRNAsRNA, CircularBioinformaticsBiomarkerCircRNA-miRNA panelClinical early detectionOvarian cancer

Identifiers

PMID40670591
PMCPMC12267751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.